ACAD Financial Facts
Net loss per common share, basic and diluted: -0.61Loss from operations: -72.4M
See Full Income Statement
See Full Balance Sheet
ACADIA Pharmaceuticals (ACAD) Earnings
|
Expand Research on ACAD
| Next EPS Date | 5/1/24 | EPS Growth Rate | +122.2% |
|---|---|---|---|
| Average EPS % Beat Rate | +22.3% | Revenue Growth Rate | +76.2% |
| Average % Move 1-Wk after EPS | -5.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/7/16  |
 |
Q316 | -$0.61 | -$0.56 | -$0.05 | $5.3M | $2.9M | N/A |  | | Details |
| 7/31/19 | |
Q219 | -$0.38 | -$0.45 | +$0.07 | $93.2M | $72.12M |  |
| | Details |
| 8/8/17 | |
Q217 | -$0.55 | -$0.72 | +$0.17 | $30.48M | $20.02M | = | | | Details |
| 5/4/18 | |
Q118 | -$0.44 | -$0.56 | +$0.12 | $48.9M | $47.06M | = | | | Details |
| 5/5/21 | |
Q121 | -$0.42 | -$0.53 | +$0.11 | $106.6M | $111.63M | N/A | | | Details |
| 5/1/19 | |
Q119 | -$0.59 | -$0.52 | -$0.07 | $62.96M | $60.69M | |
| | Details |
| 2/26/19 | |
Q418 | -$0.50 | -$0.55 | +$0.05 | $59.6M | $59.46M | |
| | Details |
| 2/27/23 | Q422 | -$0.26 | -$0.25 | -$0.01 | $136.5M | $134.23M | = | | | Details |
